Black Diamond Therapeutics Management
Management criteria checks 3/4
Black Diamond Therapeutics' CEO is Mark Velleca, appointed in Sep 2023, has a tenure of 2.08 years. total yearly compensation is $2.86M, comprised of 22.6% salary and 77.4% bonuses, including company stock and options. directly owns 0.082% of the company’s shares, worth $173.53K. The average tenure of the management team and the board of directors is 3.8 years and 4.8 years respectively.
Key information
Mark Velleca
Chief executive officer
US$2.9m
Total compensation
| CEO salary percentage | 22.58% |
| CEO tenure | 2.1yrs |
| CEO ownership | 0.08% |
| Management average tenure | 3.8yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash
Aug 25We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully
May 04
Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier
Mar 25Black Diamond Therapeutics: In Decline, But Why?
Mar 13Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts
Dec 30We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Oct 30Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data
Oct 08Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive
Jun 27Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 21We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 31Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM
Jan 12Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation
Oct 26Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 05We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 16Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?
Oct 02Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?
Jul 02We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully
Jan 16We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely
Jun 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | US$14m |
| Mar 31 2025 | n/a | n/a | US$5m |
| Dec 31 2024 | US$3m | US$645k | -US$70m |
| Sep 30 2024 | n/a | n/a | -US$73m |
| Jun 30 2024 | n/a | n/a | -US$81m |
| Mar 31 2024 | n/a | n/a | -US$80m |
| Dec 31 2023 | US$3m | US$180k | -US$82m |
| Sep 30 2023 | n/a | n/a | -US$84m |
| Jun 30 2023 | n/a | n/a | -US$83m |
| Mar 31 2023 | n/a | n/a | -US$87m |
| Dec 31 2022 | US$65k | n/a | -US$91m |
| Sep 30 2022 | n/a | n/a | -US$96m |
| Jun 30 2022 | n/a | n/a | -US$109m |
| Mar 31 2022 | n/a | n/a | -US$121m |
| Dec 31 2021 | US$204k | n/a | -US$126m |
Compensation vs Market: Mark's total compensation ($USD2.86M) is above average for companies of similar size in the US market ($USD1.51M).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
CEO
Mark Velleca (61 yo)
Dr. Mark A. Velleca, M.D., Ph. D., is Director of Myeloid Therapeutics, Inc and serves as its Chairman of the Board. He serves as President & Chief Executive Officer at Black Diamond Therapeutics, Inc. sin...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 2.1yrs | US$2.86m | 0.082% $ 173.5k | |
| COO & General Counsel | 6.4yrs | US$1.41m | 0.015% $ 31.3k | |
| Chief Medical Officer | 3.3yrs | US$1.51m | 0% $ 0 | |
| Co-Founder & Chief Scientific Officer | 4.2yrs | US$347.30k | 0.17% $ 355.1k | |
| Principal Financial Officer | 4.8yrs | no data | 0.018% $ 37.9k | |
| Chief Development Officer | 2.9yrs | no data | no data |
Experienced Management: BDTX's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 4.2yrs | US$2.86m | 0.082% $ 173.5k | |
| Independent Director | 8.6yrs | US$162.35k | 0.13% $ 285.9k | |
| Independent Director | 4.8yrs | US$186.75k | 0.018% $ 37.3k | |
| Lead Independent Director | 5.9yrs | US$171.35k | 0% $ 0 | |
| Independent Director | 1.5yrs | US$356.90k | 0.046% $ 98.3k | |
| Independent Director | 1.5yrs | US$352.20k | 0.016% $ 33.1k | |
| Independent Director | 6.8yrs | US$159.85k | 0.14% $ 303.8k |
Experienced Board: BDTX's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 11:53 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Black Diamond Therapeutics, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Arlinda Lee | Canaccord Genuity |
| Ilya Zubkov | Freedom Broker |